A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy.
JCI Insight
; 7(22)2022 11 22.
Article
en En
| MEDLINE
| ID: mdl-36509287
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Receptores de HFE
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article